Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of NRSN is 73.6 and suggests 2.89E+03% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to